Alarelin API (CAS 79561-22-1) is a high-purity, pharmaceutical-grade GnRH Agonist synthesized via advanced solid-phase peptide synthesis, fully complying with USP and EP quality standards. Its molecular structure mimics natural gonadotropin-releasing hormone, enabling it to selectively bind to pituitary GnRH receptors, initially stimulating and then downregulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Produced with strict control over peptide purity (≥99%) and biological activity, each batch undergoes rigorous validation, making it a reliable raw material for hormone-regulating drug formulation.
This potent peptide agonist stands out for its long-acting and targeted hormone-modulating effects, ideal for treating hormone-dependent conditions such as endometriosis, uterine fibroids, and precocious puberty. Unlike non-specific hormone therapies, it offers precise control over reproductive hormone levels, minimizing systemic side effects. Its stable chemical structure supports formulation into injectable solutions and sustained-release preparations, catering to diverse clinical needs for long-term treatment.
Alarelin API (CAS 79561-22-1) caters to professional users: pharmaceutical manufacturers developing endocrine medications, biotech firms advancing reproductive therapy drugs, and research institutions studying hormone regulation. Its proven clinical efficacy, pharmaceutical-grade purity, and targeted mechanism make it a top choice for buyers prioritizing reliability and therapeutic precision. Whether for large-scale commercial production or preclinical research, this GnRH Agonist meets the stringent demands of the global endocrine pharmaceutical sector.
